StockNews.com Begins Coverage on Tonix Pharmaceuticals (NASDAQ:TNXP)

StockNews.com initiated coverage on shares of Tonix Pharmaceuticals (NASDAQ:TNXP) in a report released on Thursday morning. The brokerage issued a sell rating on the stock.

Tonix Pharmaceuticals Price Performance

NASDAQ:TNXP opened at $0.19 on Thursday. The company has a market capitalization of $35.51 million, a P/E ratio of 0.00 and a beta of 2.06. The business’s 50-day moving average is $0.15 and its 200 day moving average is $1.21. The company has a current ratio of 3.33, a quick ratio of 2.81 and a debt-to-equity ratio of 0.07. Tonix Pharmaceuticals has a 12 month low of $0.12 and a 12 month high of $22.14.

Tonix Pharmaceuticals (NASDAQ:TNXP) last issued its quarterly earnings data on Tuesday, November 12th. The company reported ($0.23) earnings per share (EPS) for the quarter, topping the consensus estimate of ($2.03) by $1.80. Tonix Pharmaceuticals had a negative return on equity of 163.95% and a negative net margin of 1,197.86%. The business had revenue of $2.82 million for the quarter, compared to analysts’ expectations of $2.63 million. On average, equities research analysts forecast that Tonix Pharmaceuticals will post -18 earnings per share for the current fiscal year.

Institutional Trading of Tonix Pharmaceuticals

An institutional investor recently raised its position in Tonix Pharmaceuticals stock. Acadian Asset Management LLC boosted its stake in shares of Tonix Pharmaceuticals Holding Corp. (NASDAQ:TNXP) by 260.6% during the 1st quarter, according to its most recent disclosure with the Securities and Exchange Commission (SEC). The fund owned 335,373 shares of the company’s stock after acquiring an additional 242,358 shares during the quarter. Acadian Asset Management LLC owned about 0.40% of Tonix Pharmaceuticals worth $61,000 as of its most recent SEC filing. 82.26% of the stock is currently owned by institutional investors and hedge funds.

About Tonix Pharmaceuticals

Tonix Pharmaceuticals Holding Corp., a biopharmaceutical company, focuses on developing, discovering, commercializing, and licensing therapeutics to treat and prevent human disease and alleviate suffering. It markets Zembrace SymTouch and Tosymra for the treatment of acute migraine with or without aura in adults.